These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 7609079)

  • 1. Interactions of thyroid hormone receptor with the human immunodeficiency virus type 1 (HIV-1) long terminal repeat and the HIV-1 Tat transactivator.
    Desai-Yajnik V; Hadzic E; Modlinger P; Malhotra S; Gechlik G; Samuels HH
    J Virol; 1995 Aug; 69(8):5103-12. PubMed ID: 7609079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The NF-kappa B and Sp1 motifs of the human immunodeficiency virus type 1 long terminal repeat function as novel thyroid hormone response elements.
    Desai-Yajnik V; Samuels HH
    Mol Cell Biol; 1993 Aug; 13(8):5057-69. PubMed ID: 8393143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct transcriptional pathways of TAR-dependent and TAR-independent human immunodeficiency virus type-1 transactivation by Tat.
    Yang L; Morris GF; Lockyer JM; Lu M; Wang Z; Morris CB
    Virology; 1997 Aug; 235(1):48-64. PubMed ID: 9300036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transdominant mutants of I kappa B alpha block Tat-tumor necrosis factor synergistic activation of human immunodeficiency virus type 1 gene expression and virus multiplication.
    Beauparlant P; Kwon H; Clarke M; Lin R; Sonenberg N; Wainberg M; Hiscott J
    J Virol; 1996 Sep; 70(9):5777-85. PubMed ID: 8709193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A unique thyroid hormone response element in the human immunodeficiency virus type 1 long terminal repeat that overlaps the Sp1 binding sites.
    Rahman A; Esmaili A; Saatcioglu F
    J Biol Chem; 1995 Dec; 270(52):31059-64. PubMed ID: 8537364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus nuclear antigen 2 transactivates the long terminal repeat of human immunodeficiency virus type 1.
    Scala G; Quinto I; Ruocco MR; Mallardo M; Ambrosino C; Squitieri B; Tassone P; Venuta S
    J Virol; 1993 May; 67(5):2853-61. PubMed ID: 8386279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The human immunodeficiency virus type 1 Tat antagonist, Ro 5-3335, predominantly inhibits transcription initiation from the viral promoter.
    Cupelli LA; Hsu MC
    J Virol; 1995 Apr; 69(4):2640-3. PubMed ID: 7884917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in the conserved C-terminal sequence in thyroid hormone receptor dissociate hormone-dependent activation from interference with AP-1 activity.
    Saatcioglu F; Lopez G; West BL; Zandi E; Feng W; Lu H; Esmaili A; Apriletti JW; Kushner PJ; Baxter JD; Karin M
    Mol Cell Biol; 1997 Aug; 17(8):4687-95. PubMed ID: 9234725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Tat-mediated transactivation of HIV-1 LTR transcription by polyamide nucleic acid targeted to TAR hairpin element.
    Mayhood T; Kaushik N; Pandey PK; Kashanchi F; Deng L; Pandey VN
    Biochemistry; 2000 Sep; 39(38):11532-9. PubMed ID: 10995220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 Tat protein can transactivate a heterologous TATAA element independent of viral promoter sequences and the trans-activation response element.
    Roebuck KA; Rabbi MF; Kagnoff MF
    AIDS; 1997 Feb; 11(2):139-46. PubMed ID: 9030359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The VP16 transcription activation domain is functional when targeted to a promoter-proximal RNA sequence.
    Tiley LS; Madore SJ; Malim MH; Cullen BR
    Genes Dev; 1992 Nov; 6(11):2077-87. PubMed ID: 1427073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Camptothecin inhibits Tat-mediated transactivation of type 1 human immunodeficiency virus.
    Li CJ; Wang C; Pardee AB
    J Biol Chem; 1994 Mar; 269(10):7051-4. PubMed ID: 8125909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-site long terminal repeat (LTR) revertants of replication-defective human immunodeficiency virus: effects of revertant TATA box motifs on virus infectivity, LTR-directed expression, in vitro RNA synthesis, and binding of basal transcription factors TFIID and TFIIA.
    Kashanchi F; Shibata R; Ross EK; Brady JN; Martin MA
    J Virol; 1994 May; 68(5):3298-307. PubMed ID: 8151790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cooperative inhibition of NF-kappa B and Tat-induced superactivation of human immunodeficiency virus type 1 long terminal repeat.
    Biswas DK; Ahlers CM; Dezube BJ; Pardee AB
    Proc Natl Acad Sci U S A; 1993 Dec; 90(23):11044-8. PubMed ID: 8248210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and characterization of an HIV-1 Tat antagonist.
    Hsu MC; Schutt AD; Holly M; Slice LW; Sherman MI; Richman DD; Potash MJ; Volsky DJ
    Biochem Soc Trans; 1992 May; 20(2):525-31. PubMed ID: 1397654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 10-amino-acid sequence in the N-terminal A/B domain of thyroid hormone receptor alpha is essential for transcriptional activation and interaction with the general transcription factor TFIIB.
    Hadzic E; Desai-Yajnik V; Helmer E; Guo S; Wu S; Koudinova N; Casanova J; Raaka BM; Samuels HH
    Mol Cell Biol; 1995 Aug; 15(8):4507-17. PubMed ID: 7623841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of the human immunodeficiency virus type 1 long terminal repeat: interactions of thyroid hormone receptor with retinoid-X receptor, nuclear factor kappa B, Sp1, and Tat.
    Desai-Yajnik V; Samuels HH
    Trans Assoc Am Physicians; 1993; 106():13-32. PubMed ID: 8036737
    [No Abstract]   [Full Text] [Related]  

  • 18. Constitutive activation of gene expression by thyroid hormone receptor results from reversal of p53-mediated repression.
    Qi JS; Desai-Yajnik V; Yuan Y; Samuels HH
    Mol Cell Biol; 1997 Dec; 17(12):7195-207. PubMed ID: 9372952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cooperation between herpes simplex virus type 1-encoded ICP0 and Tat to support transcription of human immunodeficiency virus type 1 long terminal repeat in vivo can occur in the absence of the TAR binding site.
    Schafer SL; Vlach J; Pitha PM
    J Virol; 1996 Oct; 70(10):6937-46. PubMed ID: 8794337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo binding of human immunodeficiency virus type 1 Tat protein and Sp1 transcription factor.
    Jeang KT; Chun R; Lin NH; Gatignol A; Glabe CG; Fan H
    J Virol; 1993 Oct; 67(10):6224-33. PubMed ID: 7690421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.